S&P 500   3,142.41 (+0.32%)
DOW   27,900.88 (+0.07%)
QQQ   205.04 (+0.56%)
AAPL   270.44 (+0.73%)
FB   202.36 (+0.74%)
MSFT   151.83 (+0.46%)
GOOGL   1,345.07 (+0.16%)
AMZN   1,748.14 (+0.51%)
CGC   20.37 (+1.39%)
NVDA   217.16 (+1.49%)
MU   49.22 (+3.71%)
BABA   204.65 (+2.10%)
GE   11.04 (+0.27%)
TSLA   355.17 (+1.81%)
T   38.19 (+0.34%)
AMD   39.42 (-0.05%)
ACB   2.47 (-1.98%)
F   9.13 (+0.66%)
PRI   135.25 (-0.01%)
NFLX   298.45 (+1.82%)
BAC   33.71 (+0.54%)
GILD   67.89 (+1.21%)
DIS   147.58 (+1.01%)
S&P 500   3,142.41 (+0.32%)
DOW   27,900.88 (+0.07%)
QQQ   205.04 (+0.56%)
AAPL   270.44 (+0.73%)
FB   202.36 (+0.74%)
MSFT   151.83 (+0.46%)
GOOGL   1,345.07 (+0.16%)
AMZN   1,748.14 (+0.51%)
CGC   20.37 (+1.39%)
NVDA   217.16 (+1.49%)
MU   49.22 (+3.71%)
BABA   204.65 (+2.10%)
GE   11.04 (+0.27%)
TSLA   355.17 (+1.81%)
T   38.19 (+0.34%)
AMD   39.42 (-0.05%)
ACB   2.47 (-1.98%)
F   9.13 (+0.66%)
PRI   135.25 (-0.01%)
NFLX   298.45 (+1.82%)
BAC   33.71 (+0.54%)
GILD   67.89 (+1.21%)
DIS   147.58 (+1.01%)
S&P 500   3,142.41 (+0.32%)
DOW   27,900.88 (+0.07%)
QQQ   205.04 (+0.56%)
AAPL   270.44 (+0.73%)
FB   202.36 (+0.74%)
MSFT   151.83 (+0.46%)
GOOGL   1,345.07 (+0.16%)
AMZN   1,748.14 (+0.51%)
CGC   20.37 (+1.39%)
NVDA   217.16 (+1.49%)
MU   49.22 (+3.71%)
BABA   204.65 (+2.10%)
GE   11.04 (+0.27%)
TSLA   355.17 (+1.81%)
T   38.19 (+0.34%)
AMD   39.42 (-0.05%)
ACB   2.47 (-1.98%)
F   9.13 (+0.66%)
PRI   135.25 (-0.01%)
NFLX   298.45 (+1.82%)
BAC   33.71 (+0.54%)
GILD   67.89 (+1.21%)
DIS   147.58 (+1.01%)
S&P 500   3,142.41 (+0.32%)
DOW   27,900.88 (+0.07%)
QQQ   205.04 (+0.56%)
AAPL   270.44 (+0.73%)
FB   202.36 (+0.74%)
MSFT   151.83 (+0.46%)
GOOGL   1,345.07 (+0.16%)
AMZN   1,748.14 (+0.51%)
CGC   20.37 (+1.39%)
NVDA   217.16 (+1.49%)
MU   49.22 (+3.71%)
BABA   204.65 (+2.10%)
GE   11.04 (+0.27%)
TSLA   355.17 (+1.81%)
T   38.19 (+0.34%)
AMD   39.42 (-0.05%)
ACB   2.47 (-1.98%)
F   9.13 (+0.66%)
PRI   135.25 (-0.01%)
NFLX   298.45 (+1.82%)
BAC   33.71 (+0.54%)
GILD   67.89 (+1.21%)
DIS   147.58 (+1.01%)
Log in

NASDAQ:AMGN - Amgen Stock Price, Forecast & News

$234.02
+0.19 (+0.08 %)
(As of 12/11/2019 03:03 PM ET)
Today's Range
$233.03
Now: $234.03
$234.97
50-Day Range
$202.19
MA: $222.02
$234.72
52-Week Range
$166.30
Now: $234.03
$235.80
Volume829,477 shs
Average Volume2.85 million shs
Market Capitalization$139.05 billion
P/E Ratio16.25
Dividend Yield2.49%
Beta1.12
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMGN
CUSIP03116210
Phone805-447-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.75 billion
Cash Flow$18.10 per share
Book Value$19.62 per share

Profitability

Net Income$8.39 billion

Miscellaneous

Employees21,500
Market Cap$139.05 billion
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.


Amgen (NASDAQ:AMGN) Frequently Asked Questions

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Tuesday, October 22nd. Shareholders of record on Friday, November 15th will be paid a dividend of $1.45 per share on Friday, December 6th. This represents a $5.80 dividend on an annualized basis and a yield of 2.48%. The ex-dividend date of this dividend is Thursday, November 14th. View Amgen's Dividend History.

How will Amgen's stock buyback program work?

Amgen declared that its Board of Directors has approved a stock repurchase program on Friday, February 2nd 2018, which permits the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's leadership believes its stock is undervalued.

How were Amgen's earnings last quarter?

Amgen, Inc. (NASDAQ:AMGN) issued its earnings results on Tuesday, October, 29th. The medical research company reported $3.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.53 by $0.13. The medical research company had revenue of $5.74 billion for the quarter, compared to analysts' expectations of $5.63 billion. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The company's revenue for the quarter was down 2.8% compared to the same quarter last year. During the same period in the prior year, the business earned $3.69 earnings per share. View Amgen's Earnings History.

When is Amgen's next earnings date?

Amgen is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Amgen.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of $$14.50-14.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $$14.44. The company issued revenue guidance of $$23.1-23.3 billion, compared to the consensus revenue estimate of $$23.01 billion.

What price target have analysts set for AMGN?

20 brokers have issued 1 year price targets for Amgen's stock. Their forecasts range from $198.00 to $265.00. On average, they anticipate Amgen's stock price to reach $225.94 in the next twelve months. This suggests that the stock has a possible downside of 3.5%. View Analyst Price Targets for Amgen.

What is the consensus analysts' recommendation for Amgen?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 8 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:
  • 1. William Blair analysts commented, "We ultimately view the deal as positive for Amgen and a good fit for management’s strategy given the low-risk nature of the deal and immediate accretion." (8/30/2019)
  • 2. Evercore ISI analysts commented, "We used a discount rate which is a function of cost of equity and cost of debt. Terminal growth rate estimates were used to derive future cash flows." (8/11/2019)
  • 3. According to Zacks Investment Research, "While Amgen’s newer drugs — Prolia, Xgeva, Blincyto, Kyprolis — will drive sales, biosimilar and brand competition faced by its legacy drugs will create pressure on the top line in 2019. Meanwhile, uptake of key drug, Repatha has been slow due to payer restrictions. However, Amgen is progressing well with its pipeline and approval of Aimovig was a huge boost. In the past five years, Amgen has launched nine products, including two in new therapeutic areas. Amgen boasts a strong biosimilars pipeline, which could be an important long-term growth driver for the company. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some support to the bottom line. Amgen’s shares have underperformed the industry this year so far. Estimates have declined lightly ahead of the Q1 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (4/15/2019)
  • 4. Mizuho analysts commented, "We think the peak sales potential of Vascepa is underappreciated. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35." (4/12/2019)
  • 5. Cantor Fitzgerald analysts commented, ". We Reiterate our Neutral rating and $221 Price Target. We are attending the AACR (cancer research meeting) in Atlanta. Amgen presented its preclinical data for 24-minute session. The company’s molecule is targeting the KRAS p.G12C mutation and is a covalent inhibitor. The presentation explained how it identified a unique groove formed by rotation of an adjacent histidine residue (H95). An inactive form of KRAS reveals a small pocket P2 in GDP-KRAS, which is adjacent to cys12. The molecule binds to P2 and H95 and is expected to be dosed orally once daily. 510 has single-digit nanomolar potency and is 1,000x more selective to other KRAS mutants." (4/1/2019)

Has Amgen been receiving favorable news coverage?

Media coverage about AMGN stock has been trending neutral recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amgen earned a coverage optimism score of 0.5 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Amgen.

Are investors shorting Amgen?

Amgen saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 9,180,000 shares, an increase of 7.1% from the September 15th total of 8,570,000 shares. Based on an average trading volume of 2,890,000 shares, the short-interest ratio is presently 3.2 days. Approximately 1.5% of the company's shares are sold short. View Amgen's Current Options Chain.

Who are some of Amgen's key competitors?

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Alibaba Group (BABA), NVIDIA (NVDA), Intel (INTC), Walt Disney (DIS), AT&T (T), Cisco Systems (CSCO), Home Depot (HD), JPMorgan Chase & Co. (JPM) and Gilead Sciences (GILD).

Who are Amgen's key executives?

Amgen's management team includes the folowing people:
  • Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 56)
  • Mr. David W. Meline, Exec. VP & CFO (Age 62)
  • Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 58)
  • Dr. David M. Reese M.D., Exec. VP of R&D (Age 56)
  • Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 52)

Who are Amgen's major shareholders?

Amgen's stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (4.37%), Sumitomo Mitsui Trust Holdings Inc. (0.40%), Parametric Portfolio Associates LLC (0.40%), California Public Employees Retirement System (0.26%), Pictet Asset Management Ltd. (0.25%) and Man Group plc (0.18%). Company insiders that own Amgen stock include Cynthia M Patton, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar, Sean E Harper and Tyler Jacks. View Institutional Ownership Trends for Amgen.

Which institutional investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Assenagon Asset Management S.A., First Trust Advisors LP, Sawgrass Asset Management LLC, Candriam Luxembourg S.C.A., Sumitomo Mitsui Trust Holdings Inc., Stifel Financial Corp and Teacher Retirement System of Texas. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David W Meline, Jonathan P Graham, R Sanders Williams and Ronald D Sugar. View Insider Buying and Selling for Amgen.

Which institutional investors are buying Amgen stock?

AMGN stock was bought by a variety of institutional investors in the last quarter, including Railway Pension Investments Ltd, California Public Employees Retirement System, State of Tennessee Treasury Department, Man Group plc, Pictet Asset Management Ltd., State of New Jersey Common Pension Fund D, Wedge Capital Management L L P NC and Parametric Portfolio Associates LLC. View Insider Buying and Selling for Amgen.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $234.19.

How big of a company is Amgen?

Amgen has a market capitalization of $139.15 billion and generates $23.75 billion in revenue each year. The medical research company earns $8.39 billion in net income (profit) each year or $14.40 on an earnings per share basis. Amgen employs 21,500 workers across the globe.View Additional Information About Amgen.

What is Amgen's official website?

The official website for Amgen is http://www.amgen.com/.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]


MarketBeat Community Rating for Amgen (NASDAQ AMGN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  1,343 (Vote Outperform)
Underperform Votes:  872 (Vote Underperform)
Total Votes:  2,215
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel